Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 3:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,396 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Lymphocytic Leukemia
Interventions
Education Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Cholangiocarcinoma
Interventions
Gemcitabine, Capecitabine and Bevacizumab
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Buffalo, New York • Columbus, Ohio
Conditions
HER2-negative Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Weekly Paclitaxel, Trastuzumab, Pertuzumab, Celcuity CELx HSF
Drug · Diagnostic Test
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
43
States / cities
Colton, California • Miami Beach, Florida • Orlando, Florida + 34 more
Conditions
Uveal Melanoma
Interventions
PAC-1, Entrectinib
Drug
Lead sponsor
Arkadiusz Z. Dudek, MD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Venetoclax, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Hollywood, Florida + 15 more
Conditions
Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Terminated Phase 2 Interventional Results available

Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance

NCT00582166
Conditions
Non-Hodgkin's Lymphoma
Interventions
Ibritumomab Tiuxetan (Zevalin) + Rituximab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
42
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 38 more
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
Bevacizumab (Avastin), Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Not listed No phase listed Observational

Breast Cancer Tumor Heterogeneity

NCT02108561
Conditions
Breast Cancer
Interventions
Post Surgical Her2 testing
Other
Lead sponsor
Anne Arundel Health System Research Institute
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Annapolis, Maryland
Conditions
Healthy Volunteer
Interventions
Lebrikizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
4
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
pirfenidone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years to 84 Years
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
South San Francisco, California
Conditions
Mantle Cell Lymphoma
Interventions
Zanubrutinib, Obinutuzumab, Sonrotoclax
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Exudative Age Related Macular Degeneration
Interventions
Ranibizumab Injection [Lucentis]
Drug
Lead sponsor
Southeast Clinical Research Associates, LLC
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Charlotte, North Carolina • Statesville, North Carolina
Conditions
Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
Interventions
Glofitamab, Polatuzumab, Rituximab, Cyclophosphamide, Doxorubicin, Obinutuzumab:
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Hackensack, New Jersey • Middletown, New Jersey + 5 more
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Bevacizumab, Infusional 5-Fluorouracil
Drug
Lead sponsor
Tony Bekaii-Saab
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Allergies
Interventions
Omalizumab (Xolair®), Sodium Chloride (NaCl) 0.9 %
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
Acalabrutinib, Venetoclax
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
4
States / cities
Boston, Massachusetts • Charlotte, North Carolina • Durham, North Carolina + 1 more
Conditions
Chronic Lymphocytic Leukemia
Interventions
Obinutuzumab, Chlorambucil
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
19
States / cities
Huntsville, Alabama • Rogers, Arkansas • La Jolla, California + 16 more
Conditions
Renal Cell Carcinoma, Metastases
Interventions
Avastin (bevacizumab), Tarceva (erlotinib HCl)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
20
States / cities
Concord, California • Los Angeles, California • San Diego, California + 16 more
Conditions
Acute Myelogenous Leukemia, AML
Interventions
Venetoclax, Cytarabine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
60 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
5
States / cities
Kansas City, Kansas • New York, New York • Pittsburgh, Pennsylvania + 2 more
Conditions
Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
RO7496353, Atezolizumab, Capecitabine, S-1, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania
Conditions
Triple Negative Breast Cancer
Interventions
Temsirolimus, Cisplatin, Erlotinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Diabetic Macular Edema
Interventions
Faricimab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Arcadia, California • Campbell, California + 29 more